Aaron Sverdlov: Identifying common pathways for doxorubicin and carfilzomib-induced cardiotoxicities
Aaron Sverdlov, Professor and Director of Heart Failure and Co-Director at Newcastle Centre of Excellence in Cardio-Oncology, shared his recent article on LinkedIn:
“New Research in CardioOncology!
Excited to share our latest study in Scientific Reports: “Identifying common pathways for doxorubicin and carfilzomib-induced cardiotoxicities: transcriptomic and epigenetic profiling” by Conagh Kelly (recently awarded PhD!) and the rest of the team, led by Doan Ngo.
Why is this important for Cardio-Oncology?
Cardiotoxicity is a major challenge in cancer treatment. As survival rates improve, the long-term cardiovascular effects of anti-cancer drugs must be better understood. Despite being from different drug classes, both doxorubicin (anthracycline) and carfilzomib (proteasome inhibitor) can cause heart failure—highlighting the urgent need to uncover common mechanisms of cardiotoxicity.
Our Study Reveals:
- Shared transcriptomic & epigenetic changes in cardiomyocytes treated with doxorubicin and carfilzomib.
- The PI3K-Akt signaling pathway may be a key driver of cardiotoxicity across both drugs, offering potential therapeutic targets.
- Overlapping DNA methylation and gene expression changes, emphasizing the need for broad cardioprotective strategies rather than drug-specific approaches.
Why does this matter?
Understanding common mechanisms of cardiotoxicity across multiple anti-cancer drugs is crucial to developing targeted cardioprotective interventions. This research paves the way for precision cardio-oncology, ensuring cancer patients not only survive but thrive with a healthy heart.
Read the full study.”
Authors: Conagh Kelly, et al.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023